211 related articles for article (PubMed ID: 21756074)
1. Crafting a robust business model for orphan drug development.
Philippidis A
Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
[No Abstract] [Full Text] [Related]
2. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
[TBL] [Abstract][Full Text] [Related]
3. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
4. Law and research could add up to profitable niche drugs.
Haefner B
Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
[No Abstract] [Full Text] [Related]
5. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
Wood J; Sames L; Moore A; Ekins S
Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
[TBL] [Abstract][Full Text] [Related]
6. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
7. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
8. Quantitative analysis to guide orphan drug development.
Lesko LJ
Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
[TBL] [Abstract][Full Text] [Related]
9. New models for pharmaceutical innovation in low-income countries.
Ardal C; Iversen JH; Myhr K
Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
[No Abstract] [Full Text] [Related]
10. Big pharma moves from 'blockbusters' to 'niche busters'.
Dolgin E
Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
[No Abstract] [Full Text] [Related]
11. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
Swinney DC
Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
[TBL] [Abstract][Full Text] [Related]
12. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
13. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
14. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.
Engstrom LO
Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295
[No Abstract] [Full Text] [Related]
15. Drug labels: a flawed source of data for studying orphan drug approvals.
Kesselheim AS; Avorn J
Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
[No Abstract] [Full Text] [Related]
16. The role of academic institutions in the development of drugs for rare and neglected diseases.
Coles LD; Cloyd JC
Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
[TBL] [Abstract][Full Text] [Related]
17. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
18. Promoting the development of drugs against rare diseases: what more should be done?
Westermark K; Llinares J
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
[No Abstract] [Full Text] [Related]
19. FDA program could boost treatments for neglected diseases.
Traynor K
Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
[No Abstract] [Full Text] [Related]
20. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]